Who are Ketoconazole, Hydrocortisone and Dutasteride's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketoconazole-hydrocortisone-and-dutasteride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ketoconazole, Hydrocortisone and Dutasteride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketoconazole, Hydrocortisone and Dutasteride (Ketoconazole, Hydrocortisone and Dutasteride) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal, 5α-reductase inhibitor, Corticosteroid. Area: Infectious Disease, Dermatology, Oncology.

phase 2 Antifungal, 5α-reductase inhibitor, Corticosteroid Lanosterol 14α-demethylase, 5α-reductase, Glucocorticoid receptor Infectious Disease, Dermatology, Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ketoconazole, Hydrocortisone and Dutasteride (Ketoconazole, Hydrocortisone and Dutasteride) — Beth Israel Deaconess Medical Center. Ketoconazole is an antifungal that inhibits lanosterol 14α-demethylase, Dutasteride is a 5α-reductase inhibitor, and Hydrocortisone is a corticosteroid that acts as a glucocorticoid receptor agonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketoconazole, Hydrocortisone and Dutasteride TARGET	Ketoconazole, Hydrocortisone and Dutasteride	Beth Israel Deaconess Medical Center	phase 2	Antifungal, 5α-reductase inhibitor, Corticosteroid	Lanosterol 14α-demethylase, 5α-reductase, Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal, 5α-reductase inhibitor, Corticosteroid class)

Beth Israel Deaconess Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketoconazole, Hydrocortisone and Dutasteride — Competitive Intelligence Brief. https://druglandscape.com/ci/ketoconazole-hydrocortisone-and-dutasteride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab